tbuckley/cabot-search huggingface dataset:
Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival
Authors: Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Erasmia Psimenou, John N Boletis, Dimitra Bacharaki, Despoina Mparmparoussi, Charis Matsouka, Stavroula Giannouli, Evangelos Terpos, Efstathios Kastritis
Journal: Blood (2016)
Peroxiredoxin-2 (Prx2) Membrane Displacement is A New Additional Factor to the Severity of β-Thalassemic Mouse Red Cell Membrane Damage.
Authors: Alessandro Mattè, Philip S. Low, Franco Turrini, Mariarita Bertoldi, Maria Estela Campanella, Antonella Pantaleo, Angela Siciliano, Lucia De Franceschi
Journal: Blood (2009)
Nation-Wide Survey of Relapsed Infantile Acute Lymphoblastic Leukemia In Japan: Treatment and Outcome From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) MLL03 Study.
Authors: Takako Miyamura, Katsuyoshi Koh, Daisuke Tomizawa, Takashi Sato, Koji Kato, Kanji Sugita, Masahiro Hirayama, Atsushi Ogawa, Yoshihiro Takahashi, Ryosei Nishimura, Hidemasa Ochiai, Yuko Nomura, Akiko Saito, Masahito Tsurusawa, Keizo Horibe, Eiichi Ishii
Journal: Blood (2010)
Correlation of Leukemia-Cell Birth Rate Measured by Heavy Water Labeling with Other Prognostic Markers in Early Stage Chronic Lymphocytic Leukemia.
Authors: Elizabeth J Murphy, Claire Emson, Laura Z. Rassenti, Gregory Hayes, Daniel Holochwost, Marc Hellerstein, Nicholas Chiorazzi, Donna Neuberg, Thomas J. Kipps, Kanti R Rai
Journal: Blood (2009)
Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia
Authors: Cecilia Y Arana Yi, Jorge Cortes, Stefan Faderl, Guillermo Garcia-Manero, Marina Konopleva, Zeev Estrov, Susan O'Brien, Gautam Borthakur, Mark J. Levis, Deborah A. Thomas, Sherry A. Pierce, Mark Brandt, Keith W. Pratz, Rajyalakshmi Luthra, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood (2012)
Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
Authors: Salman Osman, Abraham Sebastian Kanate, Pamela Bunner, Sonia Leadmon, William Tse, Aaron Cumpston, Laura Gibson, Scot Remick, Jame Abraham, Michael Craig, Sayed Mehdi Hamadani
Journal: Blood (2010)
Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.
Authors: Al-Ola Abdallah, Shebli Atrash, Jameel Muzaffar, Nisar Ahmad, Sajjad Haider, Monica Grazziutti, Senu Apewokin, Zainab Shahid, Alejandro Restrepo, Sarah Waheed, Frits van Rhee, Bart Barlogie, Saad Z Usmani
Journal: Blood (2012)
A Cross-Sectional MRI T2* Study of Pancreatic and Pituitary Hemosiderosis in 180 Thalassemia Major Patients in Hong Kong.
Authors: Wing Y. Au, Wynnie Lam, Winnie Chu, Hui-leung Yuen, S.C. Ling, S.H. Li, M.H. Chan, K.K. Lee, M.F. Law, Herman Liu, Raymond Liang, Shau-yin Ha
Journal: Blood (2007)
Mutation Screening Associated with Chromosome 7 Abnormalities Using Next Generation Whole Exome Sequencing
Authors: Naoko Hosono, Hideki Makishima, Andres Jerez, Ines Gomez-Segui, Bartlomiej Przychodzen, Mikkael A. Sekeres, Satoru Miyano, Yuichi Shiraishi, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2012)
FLT3-ITD and MLL-PTD Mutations Influence the Expression of MDR1, MRP1 and BCRP mRNA in Adult Acute Myeloid Leukemia
Authors: Barbara Nasilowska-Adamska, Iwona Solarska, Monika Paluszewska, Wieslaw Wiktor Jedrzejczak, Piotr Rzepecki, Bozena Marianska, Krzysztof Warzocha
Journal: Blood (2012)
Protein Kinase C-β Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo
Authors: Gloria Lutzny, Thomas Kocher, Martina Rudelius, Marc Schmidt-Supprian, Ludger Klein-Hitpass, Jan Dürig, Robert A.J. Oostendorp, Christian Peschel, Alexander Egle, Ingo Ringshausen
Journal: Blood (2012)
Abstract 13985: An Individualised Operation to Stabilise and Reinforce the Ascending Aorta and Root: The First 100 Patients
Authors: John Pepper, Khevan Somasundram, Tal Golesworthy, Tom Treasure
Journal: Circulation (2017)

We have designed and applied a Personalised External Aortic Root Support (PEARS) in more than 100 patients. This mesh sleeve support is constructed by 3D printing from the patient’s digital imaging...
Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised Stage I or II CD20+ Diffuse Large B-Cell Lymphoma (CISL 12-09)
Authors: Dok Hyun Yoon, Byeong Seok Sohn, Jung Yong Hong, Sung Yong Oh, Won-Sik Lee, Sang Min Lee, Deok-Hwan Yang, Jooryung Huh, Cheolwon Suh
Journal: Blood (2016)
Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma
Authors: Meletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Evangelos Eleutherakis-Papaiakovou, Dimitrios Christoulas, Evangelos Terpos, Efstathios Kastritis
Journal: Blood (2012)
R-ESHAP as Salvage Therapy for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Spanish GEL-TAMO Multicenter Study.
Authors: Alejandro Martin, Eulogio Conde, Montserrat Arnan, Miguel A. Canales, Guillermo Deben, Rafael Andreu, Antonio Salar, Pedro Garcia-Sanchez, Sara Nistal, Maria J. Requena, Eva M. Donato, Jose A. Gonzalez, Angel Leon, Concepcion Ruiz, Carlos Grande, Reyes Arranz, Soledad Duran, Sergio Ortegon, Juan N. Rodriguez, Virgilio Sandoval, Maria A. Andreu, Teresa Bernal, Miguel T. Hernandez, Eva Gonzalez-Barca, Maria D. Caballero
Journal: Blood (2007)
Clinical outcome of early development of pneumonitis in non-small cell lung cancer patients treated with durvalumab
Authors: Akira Sugimoto, Yoshitaka Zenke, Hidehiro Hojo, Masaki Nakamura, Hibiki Udagawa, Keisuke Kirita, Takaya Ikeda, Singo Matsumoto, Kiyotaka Yoh, Seiji Niho, Tetsuo Akimoto, Koichi Goto
Journal: Annals of Oncology (2019)
Targeting the ER-Mitochondrial Interface of Cell Death Sensitizes Leukemia Cells Towards Cytostatics
Authors: Fabian Koczian, Jan Vomacka, Binje Vick, Britta F Hettich, Uli Kazmaier, Stephan A Sieber, Irmela Jeremias, Angelika M Vollmar, Simone Braig
Journal: Blood (2016)
Exercise Heat Stress in Patients With and Without Type 2 Diabetes
Authors: Sean R. Notley, Martin P. Poirier, Ronald J. Sigal, Andrew D’Souza, Andreas D. Flouris, Naoto Fujii, Glen P. Kenny
Journal: JAMA (2019)

This physiology study assesses whole-body heat loss in physically active middle-aged and older men with vs without type 2 diabetes after aerobic cycling to evaluate whether type 2 diabetes impairs heat loss and by what mechanism.
Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.
Authors: Jeffrey Rubnitz, David Wichlan, Meenakshi Devidas, Jonathan Shuster, Joanne Kurtzberg, Beverly Bell, Stephen Hunger, Allen Chauvenet, Ching-Hon Pui, Bruce Camitta, Jeanette Pullen
Journal: Blood (2006)
Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV
Authors: Rüdiger Hehlmann, Michael Lauseker, Annette Schreiber, Ulrike Proetel, Lida Kalmanti, Andreas Hochhaus, Martin C. Müller, Alice Fabarius, Stefan W. Krause, Hermann Einsele, Jolanta Dengler, Christiane Falge, Gabriela M. Baerlocher, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Markus Pfirrmann, Susanne Saussele, Joerg Hasford
Journal: Blood (2013)
Use of the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in Allogeneic Transplant (alloHCT) Recipients.
Authors: Esperanza B Papadopoulos, James W Young, Nancy A. Kernan, Farid Boulad, H.R. Castro-Malaspina, Richard J O’Reilly, Susan Prockop, Andromachi Scaradavou, Joanne Taylor, Ruth Ford, Bernadette Cuello, Trudy N Small
Journal: Blood (2008)
Cooperation of Gene Mutations Including Class I, Class II and Tumor Suppressor Genes In Childhood Acute Myeloid Leukemia and Their Impacts on Survivals
Authors: Der-Cherng Liang, Lee-Yung Shih, Chao-Ping Yang, Iou-Jih Hung, Tang-Her Jaing, Hsi-Che Liu, Ting-Chi Yeh, Shih-Hsiang Chen, Jen-Yin Hou, Chang-Liang Lai, Yu-Shu Shih, Tung-Huei Lin
Journal: Blood (2010)
Adjuvant CD49d Blockade Eradicates Chemoresistant ALL
Authors: Yao-Te Hsieh, Eugene Park, Enzi Jiang, Katrin Dauber, Doreen Chudziak, Paul Schaefer, Lars Klemm, Carlton Scharman, Eun-Suk Kang, Hong-Hoe Koo, Mignon L. Loh, Wolf Karsten Hofmann, Nora Heisterkamp, Markus Muschen, Hiroyuki Shimada, Halvard Bonig, Yong-Mi Kim
Journal: Blood (2010)
Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy
Authors: Yue-Jin Wen, Weizhi Zhao, Monica Grazziutti, Wen Ling, Jeanette Lee, Susann M Szmania, Frits van Rhee, Bart Barlogie, Elias J. Anaissie
Journal: Blood (2008)
Similar Outcome Between Siblings, Unrelated Donors and Cord Blood After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in Complete Remission
Authors: Regis Peffault de Latour, Claudio G Brunstein, Raphael Porcher, Patrice Chevallier, Marie Robin, Erica D. Warlick, Alienor Xhaard, Celalettin Ustun, Nathalie Dhedin, Mohamad Mohty, Gerard Socie, Daniel J. Weisdorf
Journal: Blood (2012)
Variable Reduction Of Thrombus Formation In The Blood Of Patients Treated With Oral Factor Xa and Thrombin Inhibitors: Pathophysiologic and Therapeutic Implications
Authors: Grazia Loredana Mendolicchio, Patrizia Marchese, Corrado Lodigiani, Anna Colombo, Matteo Ferrari, Marco Scardino, Guido Grappiolo, Lidia Rota, Zaverio M Ruggeri
Journal: Blood (2013)
The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.
Authors: Kevin R. Kelly, Ronan T. Swords, Devalingam Mahalingam, Steffan T. Nawrocki, Ernest Medina, Sabrina Smith, Swaminathan Padmanabhan, Jeffrey Ecsedy, Mary R Cahill, Francis J. Giles, Jennifer S. Carew
Journal: Blood (2009)
Severe obesity in year 6 children in England reaches new high
Authors: Jacqui Wise
Journal: BMJ (2019)

New data show that 4.4% of year 6 schoolchildren in England are classified as severely obese, the highest rate on record.1 The figures from NHS Digital show that the rate of severe obesity among 10-11 year olds has increased for the fourth consecutive year, up from 3.7% in 2014-15.

The latest figures come as England’s outgoing chief medical officer, Sally Davies, called for bold action to help tackle child obesity, such as banning eating on public transport and introducing tighter rules on advertising and takeaways.2

The National Child Measurement Programme, overseen by Public Health England, measures the height and weight of over one million children in England each year. Severe …
The Prevalence of BRAF Mutations in Patients with Glioma: A Systematic Review
Authors: Saanwalshah Samir Saincher, Julian P T Higgins, Alexandra McAleenan, Kathreena M Kurian
Journal: Neuro-Oncology (2019)

Abstract Background The V600mutation in the v-raf murine sarcoma oncogene homologue B1 (BRAF) enzyme, is a potential clinically actionable target in gliomas. BRAF inhibitors are in wide clinical use for other tumour types, particularly melanoma. The prevalence of this mutation across all gliomas is not fully elucidated and is needed to inform potential screening and treatment. Methods A systematic review using articles on the MEDLINE and EMBASE databases (February 1, 2019) was carried out. A meta-analysis was conducted to calculate the prevalence of BRAF mutations in patients with gliomas across all populations and age groups in a clinical setting. Preliminary Results The review identified 75 studies including 6316 patients; the ages of participants ranged from 30 days to 90 years with a mean age of 32.75 years. Across all studies, the average prevalence of BRAF mutations was 16% (95% confidence interval (CI) from 12% to 20%) but estimates were highly variable across studies, ranging from 0% to 78%. The average prevalence of BRAF mutations in paediatric group was 15% (95% CI 10% to 20%) while the average prevalence in the adult group was 9% (95% CI 4% to 16%). Low grade gliomas had an average prevalence of 19% (95% CI 14% to 25%) compared with 7% (95% CI 4% to 11%) in high-grade gliomas. Conclusions BRAF mutations were found to be more prevalent in pediatric patients and in low grade gliomas. Screening these patients for BRAF mutations and treating them with BRAF inhibitors represents a promising area of future medical practice.
Monitoring of Dynamics of BCR-ABL Transcripts Over Time Using Digital PCR Assay In CP CML Patients After Achieving Complete Molecular Remission
Authors: Hyun-Gyung Goh, Dongho Kim, Soo-Young Choi, Soo-Hyun Kim, Jeong Lee, Young-Seok Lee, Sang-Mi Oh, Dong-Wook Kim
Journal: Blood (2010)
Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer
Authors: Shunji Takahashi, Shanu Modi, Junji Tsurutani, Ian E. Krop, Hiroji Iwata, Russell Wada, Ophelia Yin, Tushar Garimella, Masahiro Sugihara, Lin Zhang, Caleb Lee, Kaku Saito, Yui Kawasaki, Antoine Yver, Kenji Tamura
Journal: Annals of Oncology (2019)
Identification of Target Pathways Induced By the Multiple Myeloma Tumor Microenvironment Using Activity-Based Protein Profiling and Ex Vivo Protein Kinase Inhibitor Screening
Authors: Mark B Meads, Paula Oliveira, Allison Distler, Maria Silva, Karen Burger, Bin Fang, Aunshka Collins, John L. Cleveland, John M. Koomen, Ariosto Silva, Dmitri Rebatchouk, Kenneth H. Shain, William R. Roush
Journal: Blood (2016)
A negative screening of rare genetic variants in the ADIPOQ and STATH genes in cystic fibrosis
Authors: C.A.A.C. Coutinho, F.A.L. Marson, J.D. Ribeiro, C.S. Bertuzzo
Journal: Pulmonology (2019)

The phenotypic variability in cystic fibrosis (CF) is widely recognized and modulated by environmental and genetic factors, including CFTR pathogenic variants and modifier genes genetic variants. In this context, determining the presence of variants in genes involved in immune response may allow a better understanding of CF variability, mainly in lung disease. Thus, ADIPOQ and STATH genes were selected and the analysis of exons and exon/intron junctions was performed for the determination of variations in its sequence, to determine the possible genetic modulation. A total of 49 patients with CF, diagnosed for showing abnormal [chloride] levels in the sweat test, and identification of two pathogenic variants in CFTR categorized as class I and II were included. Genetic sequencing was performed for the identification of variants in the modifier genes. In our analysis, there was absence of rare genetic variants in STATH and ADIPOQ genes associated with the clinical variability. Thus, we are not able to establish an association between the disease severity and rare genetic variants in STATH and ADIPOQ genes, considering exons and exon/intron junctions. Considering the negative screening for rare genetic variants in ADIPOQ and STATH genes, it may be concluded that these genes are not associated with phenotypic modulation of CF in our population. To understand the modifier genes and its action at CF variability it is essential to promote a better overview of the disease. Also, negative reports can help to direct new studies without the use of unnecessary financial support.
Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis
Authors: Neha Bhagwat, Matthew D Keller, Raajit K. Rampal, Kaitlyn Shank, Elisa de Stanchina, Kristine Rose, Dereck Amakye, Ross L. Levine
Journal: Blood (2013)
Neovascularisation in tendinopathy: from eradication to stabilisation?
Authors: Tero AH Järvinen
Journal: British Journal of Sports Medicine (2019)

Tendinopathy is the most common disorder in sports medicine. Multiple hypotheses have been proposed for the aetiopathogenesis, but many aspects still remain elusive. Microdialysis studies have shown high levels of lactate within tendinosis, even at resting tendons,1 suggesting that hypoxia persists in tendinopathy. The presence of necrotic tenocytes, blocked arteries and anaerobic enzymes within tendinopathy lesions lend further support to the role of hypoxia in the aetiopathogenesis.2 Finally, ‘tendinosis’, the pathognomonic histopathological finding in tendinopathy, is composed of hypoxic, mucoid, hyaline and fibrinoid tissue.2 These tissue types are known to be hypoxia induced.

Tendons are generally poorly vascularised, while certain regions—those most prone to injury—are almost avascular. This can be considered an evolutionary ‘design failure’ that makes tendons susceptible to chronic and acute injuries. As a consequence, healthy tendons have a virtually non-existent tissue turnover throughout adulthood.3 However, somewhat paradoxically, tissue turnover is increased in tendinopathic tendons.3 Given the persisting hypoxia and subsequent anaerobic metabolism,1 2 it comes as no surprise that the enhanced tissue turnover leads to production of poorly organised tissue—tendinosis—in tendinopathy.2 

The fundamental survival mechanism of any cell under hypoxia is the activation of hypoxia-inducible factor-1α (HIF-1α),4 a transcription factor that turns …
Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9
Authors: Aaron Foster, Peter Chang, Pei-Yi Lin, Jeannette Crisostomo, Aruna Mahendravada, An Lu, Mariam Khalil, Sunandan Saha, Joanne Shaw, Eva Morschl, Kevin M Slawin, David M Spencer
Journal: Blood (2015)
Abstract 19086: Myofilament Proteins of the Naked Mole-rat Heart Reflect Low Basal Species Cardiac Function
Authors: Kelly M Grimes, David Barefield, Mohit Kumar, Pieter P de Tombe, Sakthivel Sadayappan, Rochelle Buffenstein
Journal: Circulation (2014)

The naked mole-rat (NMR) is a mouse-sized rodent with a maximum longevity of &gt;31 years. The species exhibits low basal heart rate (256 bpm) and cardiac output (7 ml/min) for its body size, as well as low fractional shortening (28%) for a rodent. However unlike other well-studied mammals, the NMR maintains cardiac reserve and diastolic function for at least 75% of its maximum lifespan - at ages equivalent to 90 year old humans. We questioned if this low basal cardiac function was due to NMR myofilament composition and function. NMR ventricles are comprised primarily of the β-myosin heavy chain isoform, which is associated with slowed myocardial contraction and increased efficiency. This is in stark contrast to mouse ventricles, which express predominately the α-isoform, and switch to the β-isoform upon experimental induction of heart failure. Compared to mice, NMR myofilament proteins such as cardiac troponin I and cardiac myosin binding protein-C display lower levels of phosphorylation. Such levels are indicative of decreased activation of myofilament proteins and may relate to the species’ low basal cardiac function. Both the NMR’s predominance of β-myosin heavy chain and the low basal level of myofilament phosphorylation present a phenotype much closer to that seen in human ventricles than in those of mice. Intriguingly, maximal force developed by skinned NMR cardiomyocytes is not significantly different to that of mouse cardiomyocytes (NMR: 70.9 ± 9.3mN/mm2 vs. mouse: 87.7 ± 0.6 mN/mm2). This is likely a reflection of the NMR’s ability to enhance cardiac function to the level of a mouse when stimulated, as is evident when both species are treated in vivo with dobutamine (3 μg/g i.p.). Such low basal cardiac function may put less overall strain on the heart over time and could be critical to the NMR’s ability to maintain cardiac function with age.
Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
Authors: Christian Grommes, Alessandro Pastore, Igor Gavrilovic, Thomas Kaley, Craig Nolan, Antonio M. Omuro, Julia Wolfe, Elena Pentsova, Vaois Hatzoglou, Ingo Mellinghoff, Lisa DeAngelis
Journal: Blood (2016)
Gene-Expression Profiling of Graft-Versus-Host Disease by Oligonucleotide Microarrays.
Authors: Jan Verner, Jitka Kabathova, Boris Tichy, Zbynek Zdrahal, Alexandra Tomancova, Yvona Brychtova, Michael Doubek, Marek Mraz, Jitka Malcikova, Sarka Pospisilova, Jiri Mayer
Journal: Blood (2009)
Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy
Authors: Chiara Sarlo, Maria Giovanna Cefalo, Eleonora Ceresoli, Licia Ottaviani, Selenia Campagna, Concetta Ditto, Luigi Di Caprio, Maria Ilaria Del Principe, Annibale Franchi, Luca Maurillo, Francesco Buccisano, Sergio Amadori, Adriano Venditti
Journal: Blood (2010)
Blood markers for cancer
Authors: Jessica Watson, Luke Mounce, Sarah ER Bailey, Sharon L Cooper, Willie Hamilton
Journal: BMJ (2019)

### What you need to know

A 61 year old man with a one month history of back pain visits his general practitioner (GP). He has hypertension, has never smoked, and reports fatigue for several months. The pain is keeping him awake at night. He has not lost weight. Clinical examination is normal. The differential diagnosis for this patient is wide, including potential malignant causes such as pancreatic, myeloma, and prostate cancer or metastatic disease. 

Cancer can be difficult to identify, as many of the common symptoms are non-specific and low risk, and even the most well known “alarm” symptoms have relatively low positive predictive values (PPVs) for underlying malignancy.1 For example, weight loss has a PPV for underlying malignancy of only 0-3.3%,2 while rectal bleeding has a PPV of 2.2-15.8%.3 Cancer markers used in hospital settings, when applied to low risk primary care patients, have low positive predictive values and high false positive rates.4 Identifying patients whose non-specific symptoms may be caused by cancer, rather than benign disease, is therefore a challenge for primary care physicians.

While formal diagnosis usually happens in secondary care, the first suspicion of cancer generally occurs in primary care. Patients whose symptoms represent an approximate risk of cancer of ≥3% are recommended by the National Institute for Health and Care Excellence (NICE) for urgent investigation, often by referral.5 Those with estimated risk <3% may receive …
Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.
Authors: Qaiser Bashir, Wei Wei, Alexandre Chiattone, Gabriela Rondon, Simrit Parmar, Nina Shah, Ernesto Harold Booc, Dinh Yvonne, Qureshi Sofia, Jatin J Shah, Robert Z. Orlowski, Donna Weber, Richard Champlin, Sergio Giralt, Muzaffar H. Qazilbash
Journal: Blood (2010)
Adenosine Signaling-Mediated Metabolic Reprogramming Regulates Erythropoiesis
Authors: Hong Liu, Yujin Zhang, Angelo D'Alessandro, Travis Nemkov, Jacob Couturier, Shushan Zhao, Kirk C Hansen, Andrew T. Lovering, Robert Roach, Rodney E. Kellems, Holger K. Eltzschig, Michael R. Blackburn, Yang Xia
Journal: Blood (2016)
The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,
Authors: Luhua Wang, David S. Siegel, Andrzej J Jakubowiak, Alvin F. Wong, Sandra Dixon, Thomas E Renau, Ravi Vij
Journal: Blood (2011)
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
Authors: A. Keith Stewart, S. Vincent Rajkumar, Meletios A. Dimopoulos, Tamás Masszi, Ivan Spicka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi G. Mihaylov, Veselina Goranova-Marinova, Péter Rajnics, Aleksandr Suvorov, Ruben Niesvizky, Andrzej Jakubowiak, Jesus F. San Miguel, Heinz Ludwig, Naseem Zojwalla, Margaret E. Tonda, Biao Xing, Philippe Moreau, Antonio Palumbo
Journal: Blood (2014)